Filing Details

Accession Number:
0000899243-20-034283
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-12-17 16:05:11
Reporting Period:
2020-12-15
Accepted Time:
2020-12-17 16:05:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1733294 Generation Bio Co. GBIO Pharmaceutical Preparations (2834) 814301281
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1814308 D. Mark Angelino C/O Generation Bio Co.,
301 Binney Street
Cambridge MA 02142
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-12-15 5,301 $4.59 350,938 No 4 M Direct
Common Stock Disposition 2020-12-15 4,401 $34.87 346,537 No 4 S Direct
Common Stock Disposition 2020-12-15 900 $35.52 345,637 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2020-12-15 5,301 $0.00 5,301 $4.59
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
118,460 2028-04-01 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 169,846 Indirect See Footnote
Footnotes
  1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.39 to $35.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.41 to $35.84, inclusive.
  4. The securities are directly held by the Mark D. Angelino 2020 Qualified Annuity Trust, or the Trust. Mark D. Angelino is the settlor and trustee of the Trust, and the Trust is for the benefit of Elizabeth I., Emily A., John P., and Matthew R. Angelino. The reporting person may be deemed to beneficially own the shares of common stock owned by the Trust.
  5. The option to purchase 123,761 shares was granted on April 2, 2018. The shares underlying the option vest over four years, with 25% of the shares vested on April 2, 2019 and the remaining shares vesting in equal quarterly installments thereafter.